Ultragenyx Pharmaceutical (RARE) Earning Somewhat Positive News Coverage, Analysis Shows
Media headlines about Ultragenyx Pharmaceutical (NASDAQ:RARE) have trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ultragenyx Pharmaceutical earned a news impact score of 0.21 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.771043161592 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Ultragenyx Pharmaceutical: A Pullback And Upcoming Regulatory Catalysts – Seeking Alpha (seekingalpha.com)
- Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be … – Markets Insider (markets.businessinsider.com)
- Ultragenyx Pharmaceutical Inc. (RARE) Rating Reiterated by Robert W. Baird (americanbankingnews.com)
- Brokers Offer Predictions for Ultragenyx Pharmaceutical Inc.’s Q2 2018 Earnings (RARE) (americanbankingnews.com)
Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at 52.16 on Friday. The company has a 50-day moving average price of $56.51 and a 200-day moving average price of $62.94. The stock’s market capitalization is $2.21 billion. Ultragenyx Pharmaceutical has a 12-month low of $49.56 and a 12-month high of $91.35.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.73) by $0.01. During the same period last year, the company earned ($1.46) earnings per share. On average, equities research analysts forecast that Ultragenyx Pharmaceutical will post ($7.14) earnings per share for the current year.
A number of equities research analysts have recently weighed in on the company. BidaskClub raised Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. Sanford C. Bernstein assumed coverage on Ultragenyx Pharmaceutical in a research note on Thursday, July 27th. They issued a “market perform” rating and a $72.00 price objective for the company. Canaccord Genuity set a $98.00 price objective on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research note on Friday, July 28th. ValuEngine raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Finally, Zacks Investment Research raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $71.65.
WARNING: “Ultragenyx Pharmaceutical (RARE) Earning Somewhat Positive News Coverage, Analysis Shows” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.watchlistnews.com/ultragenyx-pharmaceutical-rare-earning-somewhat-positive-news-coverage-analysis-shows/1582454.html.
In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis bought 7,500 shares of the stock in a transaction dated Monday, August 28th. The stock was bought at an average cost of $52.52 per share, for a total transaction of $393,900.00. Following the completion of the purchase, the chief executive officer now directly owns 430,569 shares of the company’s stock, valued at $22,613,483.88. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 9.20% of the stock is currently owned by corporate insiders.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.